Intra-Cellular Therapies Inc

NASDAQ:ITCI   2:41:55 PM EDT
36.75
-0.85 (-2.26%)
Products

Intra-Cellular Therapies Announces FDA Acceptance Of Caplyta® (Lumateperone) Sndas For The Treatment Of Bipolar Depression

Published: 05/03/2021 12:23 GMT
Intra-Cellular Therapies Inc (ITCI) - Intra-cellular Therapies Announces FDA Acceptance of Caplyta® (lumateperone) Sndas for the Treatment of Bipolar Depression.
Intra-cellular Therapies Inc - FDA Has Assigned a Prescription Drug User Fee Act (pdufa) Target Action Date of December 17, 2021 for Applications.
Intra-cellular Therapies Inc - Caplyta Has a Boxed Warning, is Not Approved for Treatment of Patients With Dementia-related Psychosis.